Affimed NV Cost Of Revenue Over Time
| AFMD Stock | USD 3.00 0.38 14.50% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Affimed NV Performance and Affimed NV Correlation. Affimed |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Affimed NV. If investors know Affimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Affimed NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.76) | Revenue Per Share 0.493 | Quarterly Revenue Growth (0.90) | Return On Assets (0.49) | Return On Equity (1.24) |
The market value of Affimed NV is measured differently than its book value, which is the value of Affimed that is recorded on the company's balance sheet. Investors also form their own opinion of Affimed NV's value that differs from its market value or its book value, called intrinsic value, which is Affimed NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Affimed NV's market value can be influenced by many factors that don't directly affect Affimed NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Affimed NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if Affimed NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Affimed NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Cost Of Revenue Analysis
Compare Affimed NV and related stocks such as Tcr2 Therapeutics, Pieris Pharmaceuticals, and ADC Therapeutics Cost Of Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PIRS | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (830.4 K) | (369.2 K) | 28.2 M | 39.5 M | 0.0 | 55 M | 46.5 M | 2.4 M | 2.8 M | 41.8 M | 21.2 M |
| ADCT | 85.5 M | 85.5 M | 85.5 M | 85.5 M | 85.5 M | 85.5 M | 85.5 M | 85.5 M | 118.1 M | 107.5 M | 2 M | 1.4 M | 4.6 M | 2.5 M | 2.4 M |
| AGEN | (1.3 M) | 19.6 M | 11.2 M | 13.5 M | 22.3 M | 70.4 M | 95 M | 116.1 M | 124.6 M | 168.3 M | 145 M | 182.1 M | 197.3 M | 16.7 M | 15.9 M |
| XFOR | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 672 K | 1.9 M | 1.9 M | 2 M | 2 M | 1 M |
| DAWN | 155 K | 155 K | 155 K | 155 K | 155 K | 155 K | 155 K | 155 K | 155 K | 155 K | 155 K | 199 K | 531 K | 383 K | 348.7 K |
| PDSB | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 98.4 K | 98.4 K | 176.3 K | 246.4 K | 49.1 K | 57.3 K | 98.6 K |
| INZY | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 217 K | 1.1 M | 1.2 M | 1.3 M | 841.1 K |
| LPTX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 25 K | 48 K | 49 K | 776 K | 415 K | 415 K | 415 K | 427 K | 448.4 K |
| ADAP | 9.3 M | 9.3 M | 9.3 M | 15.1 M | 33.8 M | 0.0 | 63.8 M | 87.4 M | 98.3 M | 97.5 M | 91.6 M | 111.1 M | 127.7 M | 9.9 M | 9.4 M |
| CRVS | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 148 K | 594 K | 842 K | 847 K | 743 K | 632 K | 460 K | 367 K | 151 K | 143.4 K |
| APTO | (68.7 K) | 0.0 | 0.0 | 0.0 | 0.0 | 69.1 K | 114.8 K | 89.1 K | 83.5 K | 627.3 K | 646.4 K | 616.5 K | 507.1 K | 474.5 K | 498.3 K |
| ELEV | 15 K | 15 K | 15 K | 15 K | 15 K | 15 K | 15 K | 15 K | 15 K | 15 K | 15 K | 18 K | 27 K | 39 K | 27.2 K |
| MREO | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 24.6 M | 34.6 M | 22.7 M | 23.6 M | 16.3 M | 17.9 M | 936 K | 2.6 M | 2.4 M |
| HEPA | 26.7 K | 26.7 K | 26.7 K | 26.7 K | 26.7 K | 26.7 K | 26.7 K | 26.7 K | 26.7 K | 26.7 K | 34.5 K | 86.1 K | 77.5 K | 67.1 K | 64.2 K |
Affimed NV and related stocks such as Tcr2 Therapeutics, Pieris Pharmaceuticals, and ADC Therapeutics Cost Of Revenue description
Cost of Revenue is found on Affimed NV income statement and represents the costs associated with goods and services Affimed NV provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.My Equities
My Current Equities and Potential Positions
| Affimed NV | AFMD |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Germany |
| Exchange | NASDAQ Exchange |
USD 3.0
Check out Affimed NV Performance and Affimed NV Correlation. For information on how to trade Affimed Stock refer to our How to Trade Affimed Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Affimed NV technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.